| __timestamp | Galapagos NV | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 111110000 | 22223073 |
| Thursday, January 1, 2015 | 129714000 | 6966842 |
| Friday, January 1, 2016 | 139574000 | 9000499 |
| Sunday, January 1, 2017 | 218502000 | 13741186 |
| Monday, January 1, 2018 | 322876000 | 19040000 |
| Tuesday, January 1, 2019 | 427320000 | 23559000 |
| Wednesday, January 1, 2020 | 523667000 | 31931000 |
| Friday, January 1, 2021 | 491707000 | 44981000 |
| Saturday, January 1, 2022 | 515083000 | 54234000 |
| Sunday, January 1, 2023 | 241294000 | 63806000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Galapagos NV and Viking Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Galapagos NV consistently outspent Viking Therapeutics, with its R&D expenses peaking in 2020 at over 500% more than Viking's. However, Viking has shown a remarkable growth trajectory, increasing its R&D spending by nearly 200% from 2014 to 2023. This trend highlights Viking's aggressive push towards innovation, especially in recent years. Meanwhile, Galapagos experienced a significant dip in 2023, reducing its R&D expenses by more than 50% compared to its 2020 peak. These spending patterns reflect strategic shifts and market dynamics, offering insights into the future directions of these biotech players.
AbbVie Inc. or Galapagos NV: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Galapagos NV
Comparing Innovation Spending: United Therapeutics Corporation and Viking Therapeutics, Inc.
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Viking Therapeutics, Inc.
Analyzing R&D Budgets: Intra-Cellular Therapies, Inc. vs Galapagos NV
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Galapagos NV
Analyzing R&D Budgets: Viking Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Protagonist Therapeutics, Inc.
Comparing Innovation Spending: HUTCHMED (China) Limited and Galapagos NV
R&D Insights: How Supernus Pharmaceuticals, Inc. and Galapagos NV Allocate Funds
Galapagos NV vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Galapagos NV vs MiMedx Group, Inc.